August 06, 2026 05:55 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
No rate cut! RBI keeps repo rate unchanged, sees 6.7% growth but warns inflation will rise | Free laptops, AI training, internships: Vijay government unveils youth-centric Tamil Nadu budget | Bangladesh asks media not to broadcast Sheikh Hasina's speech ahead of first public appearance from India | Kejriwal marches to PM Modi's residence over E20 petrol, alleges 'Trump pressure' behind policy | DMK slams Vijay government over Udhayanidhi's arrest, calls it 'blatant cowardice' | Tamil Nadu political storm: Udhayanidhi Stalin arrested after Trisha remark row | Faridabad teacher stabbed 34 times in 30 seconds at school gate; shocking CCTV details emerge | 'It was a conspiracy': Brij Bhushan reacts after acquittal in wrestlers' sexual harassment case | After NEET protests, CJP backs Jharkhand students' agitation over alleged JPSC-JSSC exam irregularities | Brij Bhushan acquitted: Delhi Court clears ex-WFI chief in high-profile wrestlers' sexual harassment case
Pregnancy
Pixabay

U.S. FDA approves first nonprescription daily oral contraceptive

| @indiablooms | Jul 14, 2023, at 03:30 pm

Los Angeles: The U.S. Food and Drug Administration (FDA) on Thursday approved Opill (norgestrel) tablet for nonprescription use to prevent pregnancy, which is the first daily oral contraceptive approved for use in the United States without a prescription.

Approval of this progestin-only oral contraceptive pill provides an option for consumers to purchase oral contraceptive medicine without a prescription at drug stores, convenience stores and grocery stores, as well as online.

Nonprescription availability of Opill may reduce barriers to access by allowing individuals to obtain an oral contraceptive without the need to first see a health care provider, said the FDA in a statement.

The most common side effects of Opill include irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA.

"Today's approval marks the first time a nonprescription daily oral contraceptive will be an available option for millions of people in the United States," said Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.